An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.
Abstract
The Kabi International Growth Study (KIGS) was first established in 1987 and is the largest pharmaco-epidemiological study of recombinant human growth hormone (rhGH). KIGS is aimed at evaluating long-term safety and treatment outcomes in pediatric subjects who received Genotropin rhGH therapy (Pfizer, New York, NY, USA) as prescribed by physicians in real-world clinical practice settings. KIGS data have been used to answer multiple research questions related to growth, growth prediction, and growth hormone treatment, leading to the publication of 129 peer-reviewed manuscripts and 24 biannual reports, outcomes from 10 expert meetings, and 3 books. The KIGS has shown that rhGH is safe and increases both the short-term height gain and adult height in patients with GH deficiency (GHD) and multiple other non-GHD conditions associated with short stature.
참고문헌 (25)
- Ranke MB, "Growth hormone-past, present and future", Nat Rev Endocrinol, 14, pp.285~300 (2018)
- Parks JS, "Gene sequence and production. of recombinant MetGH", hGH, 2018, pp.16(Suppl 1), 17~27
- "Clinical Drug Experience Knowledgebase: Kabi Pharmacia" (2003)[URL]
- Wallström A, "Progress in growth hormone therapy – 5 years of KIGS", pp.1~9 (1994), J&J Verlag
- Wilton P, "20 years of KIGS", pp.1~5 (2007), Karger
- Non-interventional study abstract for external disclosure, "Protocol A6281306(87-052). KIGS®(Pfizer International Growth Database)" (2014), Pfizer
- Ranke MB, "Progress in growth hormone therapy – 5 years of KIGS", pp.51~61 (1994), J&J Verlag
- Wilton P, "Progress in growth hormone therapy – 5 years of KIGS", pp.291~307 (1994), J&J Verlag
- Maghnie M, "Safety and efficacy of pediatric growth hormone therapy : results from the full KIGS cohort", J Clin Endocrinol Metab, 107, pp.3287~3301 (2022)
- Ranke MB, "20 Years of KIGS", pp.183~188 (2007), Karger
- Gutiérrez LP, "Registries as a tool in evidence-based medicine : example of KIMS(Pfizer International Metabolic Database)", Pharmacoepidemiol Drug Saf, 17, pp.90~102 (2008)
- Johannsson G, "Long-term safety of growth hormone in adults with growth hormone deficiency : overview of 15 809 GH-treated patients", J Clin Endocrinol Metab, 107, pp.1906~1919 (2022)
- Ranke MB, "Predicting growth in response to growth hormone treatment", Growth Horm IGF Res, 19, pp.1~11 (2009)
- Ranke MB, "20 Years of KIGS", pp.422~431 (2007), Karger
- Ranke MB, "Observed and predicted total pubertal growth during treatment with growth hormone in adolescents with idiopathic growth hormone deficiency, Turner syndrome, short stature, born small for gestational age and idiopathic short stature : KIGS analysis and review", Horm Res Paediatr, 75, pp.423~432 (2011)
- Loftus J, "Individualised growth response optimisation(iGRO)tool : an accessible and easy-to-use growth prediction system to enable treatment optimisation for children treated with growth hormone", J Pediatr Endocrinol Metab, 30, pp.1019~1026 (2017)
- Geffner M, "Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy : analysis of KIGS(Pfizer International Growth Database)", J Clin Endocrinol Metab, 89, pp.5435~5440 (2004)
- Verhelst J, "Baseline characteristics and response to 2 years of growth hormone(GH)replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma : data from KIMS(Pfizer International Metabolic Database)", J Clin Endocrinol Metab, 90, pp.4636~4643 (2005)
- Yuen KC, "Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction", Eur J Endocrinol, 169, pp.511~519 (2013)
- Yuen KC, "Primary treatment regimen and diabetes insipidus as predictors of health outcomes in adults with childhood-onset craniopharyngioma", J Clin Endocrinol Metab, 99, pp.1227~1235 (2014)
- Yuen KCJ, "Relative risks of contributing factors to morbidity and mortality in adults with craniopharyngioma on growth hormone replacement", J Clin Endocrinol Metab, 103, pp.768~777 (2018)
- Darendeliler F, "20 Years of KIGS", pp.213~239 (2007), Karger
- Ranke MB, "Progress in growth hormone therapy – 5 years of KIGS", pp.1~313 (1994), J&J Verlag
- Ranke MB, "Growth hormone therapy in KIGS – 10 years experience", pp.1~409 (1999), Johann Ambrosius Barth Verlag
- Ranke MB, "Growth hormone therapy in pediatrics – 20 years of KIGS", pp.1~511 (2007), Karger